×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Articles

Jessica Skarzynski
While universal screening for Lynch syndrome is currently only recommended for patients with colorectal and endometrial cancers, a new study recently published in The American Journal of Surgical Pathology suggests this for patients with upper tract urothelial carcinoma, too.
 
Brielle Urciuoli
Patients with head and neck cancer appeared to be receptive to lung cancer screening, according to recent research performed at the University of Iowa Hospitals and Clinics.
Geoffrey Norman
I didn’t like thinking of myself as a “survivor.” There was something … I don’t know. Something a little shameful, maybe, about it.
Kristie L. Kahl
Imagine receiving two pieces of life-altering news in a matter of three days. One survivor not only experienced this, but came out the other side with a positive outlook and a humorous book, too.
 
Kristie L. Kahl
As part of the Bristol-Myers Squibb Coast 2 Coast 4 Cancer Research ride, 109 company employees rode from Oregon to New Jersey to help raise funds for the V Foundation for Cancer Research.
Jason M. Broderick
The FDA has granted a priority designation to a supplemental new drug application (sNDA) for Imbruvica (ibrutinib) for use in combination with Gazyva (obinutuzumab) for the frontline treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Kristie L. Kahl
The amount of preventative medicines given during hospital admission may be associated with an increased amount prescribed at discharge – resulting in higher costs and an increased risk for drug-drug interactions in patients with advanced lung cancer.
 
Brielle Urciuoli
As marijuana use continues to increase across the US – and become legalized in more states – understanding the potential negative health effects is paramount. 
Katie Kosko
Patients with the disease reported increased feelings of stigmatization, and results also showed that patients are viewed or treated differently than those with other cancer types.
Brielle Urciuoli
With this FDA action, Talzenna (talazoparib) is the second PARP inhibitor to be approved in the breast cancer space.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other